Antileukemic activity of 1-β-D-arabinofuranosyl-2-amino-1,4(2H)-4-iminopyrimidine, a new depot form of 1-β-D-arabinofuranosylcytosine

T. A. Khwaja, L. J. Kigwana, A. M. Mian

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

1-β-D-Arabinofuranosyl-2-amino-1,4(2H)-4-iminopyrimidine (ara-AlPy) and its 3'-phosphate (ara-AIPyP) have been synthesized and have been shown to be very effective in the treatment of leukemia L1210 in female C57BL/6 x DBA/2 (hereafter known as BDF1) mice (ara-AIPy increased life span 222% and cured 21 of 30 animals, ara-AIPyp increased life span 145% and cured 2 of 6 animals). The antileukemic activity of ara-AIPy is comparable to that of anhydro-ara-C. ara-AIPyP was also effective (i.p. treatments) against intracerebrally implanted leukemia L1210 in female BDF1 mice (increased life span 126%, cured 1 of 6 animals), ara-AIPyp was not active against a leukemia L1210 strain which was resistant to ara-C treatments. ara-AIPy and ara-AIPyP were not substrates for enzymic deamination by crude extracts of Escherichia coli. ara-AIPyP was a substrate for E. coli alkaline phosphatase. In a Tris-HCl buffer (pH 7.4, 37°) ara-AIPy hydrolyzed to provide 2,2'-anhydro-1-β-D-arabinofuranosylcytosine and 1-β-D-arabinofuranosylcytosine (ara-C). Most of the ara-C produced by hydrolysis of ara-AIPy over a 24-hr period was due to direct deamination of ara-AIPy. Some ara-C (<10%) was also produced due to the hydrolysis of 2,2'-anhydro-1-β-D-arabinofuranosylcytosine. Under identical conditions of hydrolysis, ara-AIPyP gave 2-2'-anhydro-β-D-arabinofuranosylcytosine 3'-phosphate and 1-β-D-arabinofuranosylcytosine 3'-phosphate. Studies illustrate that ara-AIPy and ara-AIPyP are new deaminase-resistant depot forms of ara-C.

Original languageEnglish
Pages (from-to)3129-3133
Number of pages5
JournalCancer Research
Volume39
Issue number8
StatePublished - Dec 1 1979
Externally publishedYes

Fingerprint

Cytarabine
Leukemia L1210
Deamination
Hydrolysis
Phosphates
Ancitabine
Escherichia coli
Tromethamine
araAIPy
Complex Mixtures
Alkaline Phosphatase

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Antileukemic activity of 1-β-D-arabinofuranosyl-2-amino-1,4(2H)-4-iminopyrimidine, a new depot form of 1-β-D-arabinofuranosylcytosine. / Khwaja, T. A.; Kigwana, L. J.; Mian, A. M.

In: Cancer Research, Vol. 39, No. 8, 01.12.1979, p. 3129-3133.

Research output: Contribution to journalArticle

@article{41146d5299ac41c198afe498a8474545,
title = "Antileukemic activity of 1-β-D-arabinofuranosyl-2-amino-1,4(2H)-4-iminopyrimidine, a new depot form of 1-β-D-arabinofuranosylcytosine",
abstract = "1-β-D-Arabinofuranosyl-2-amino-1,4(2H)-4-iminopyrimidine (ara-AlPy) and its 3'-phosphate (ara-AIPyP) have been synthesized and have been shown to be very effective in the treatment of leukemia L1210 in female C57BL/6 x DBA/2 (hereafter known as BDF1) mice (ara-AIPy increased life span 222{\%} and cured 21 of 30 animals, ara-AIPyp increased life span 145{\%} and cured 2 of 6 animals). The antileukemic activity of ara-AIPy is comparable to that of anhydro-ara-C. ara-AIPyP was also effective (i.p. treatments) against intracerebrally implanted leukemia L1210 in female BDF1 mice (increased life span 126{\%}, cured 1 of 6 animals), ara-AIPyp was not active against a leukemia L1210 strain which was resistant to ara-C treatments. ara-AIPy and ara-AIPyP were not substrates for enzymic deamination by crude extracts of Escherichia coli. ara-AIPyP was a substrate for E. coli alkaline phosphatase. In a Tris-HCl buffer (pH 7.4, 37°) ara-AIPy hydrolyzed to provide 2,2'-anhydro-1-β-D-arabinofuranosylcytosine and 1-β-D-arabinofuranosylcytosine (ara-C). Most of the ara-C produced by hydrolysis of ara-AIPy over a 24-hr period was due to direct deamination of ara-AIPy. Some ara-C (<10{\%}) was also produced due to the hydrolysis of 2,2'-anhydro-1-β-D-arabinofuranosylcytosine. Under identical conditions of hydrolysis, ara-AIPyP gave 2-2'-anhydro-β-D-arabinofuranosylcytosine 3'-phosphate and 1-β-D-arabinofuranosylcytosine 3'-phosphate. Studies illustrate that ara-AIPy and ara-AIPyP are new deaminase-resistant depot forms of ara-C.",
author = "Khwaja, {T. A.} and Kigwana, {L. J.} and Mian, {A. M.}",
year = "1979",
month = "12",
day = "1",
language = "English",
volume = "39",
pages = "3129--3133",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Antileukemic activity of 1-β-D-arabinofuranosyl-2-amino-1,4(2H)-4-iminopyrimidine, a new depot form of 1-β-D-arabinofuranosylcytosine

AU - Khwaja, T. A.

AU - Kigwana, L. J.

AU - Mian, A. M.

PY - 1979/12/1

Y1 - 1979/12/1

N2 - 1-β-D-Arabinofuranosyl-2-amino-1,4(2H)-4-iminopyrimidine (ara-AlPy) and its 3'-phosphate (ara-AIPyP) have been synthesized and have been shown to be very effective in the treatment of leukemia L1210 in female C57BL/6 x DBA/2 (hereafter known as BDF1) mice (ara-AIPy increased life span 222% and cured 21 of 30 animals, ara-AIPyp increased life span 145% and cured 2 of 6 animals). The antileukemic activity of ara-AIPy is comparable to that of anhydro-ara-C. ara-AIPyP was also effective (i.p. treatments) against intracerebrally implanted leukemia L1210 in female BDF1 mice (increased life span 126%, cured 1 of 6 animals), ara-AIPyp was not active against a leukemia L1210 strain which was resistant to ara-C treatments. ara-AIPy and ara-AIPyP were not substrates for enzymic deamination by crude extracts of Escherichia coli. ara-AIPyP was a substrate for E. coli alkaline phosphatase. In a Tris-HCl buffer (pH 7.4, 37°) ara-AIPy hydrolyzed to provide 2,2'-anhydro-1-β-D-arabinofuranosylcytosine and 1-β-D-arabinofuranosylcytosine (ara-C). Most of the ara-C produced by hydrolysis of ara-AIPy over a 24-hr period was due to direct deamination of ara-AIPy. Some ara-C (<10%) was also produced due to the hydrolysis of 2,2'-anhydro-1-β-D-arabinofuranosylcytosine. Under identical conditions of hydrolysis, ara-AIPyP gave 2-2'-anhydro-β-D-arabinofuranosylcytosine 3'-phosphate and 1-β-D-arabinofuranosylcytosine 3'-phosphate. Studies illustrate that ara-AIPy and ara-AIPyP are new deaminase-resistant depot forms of ara-C.

AB - 1-β-D-Arabinofuranosyl-2-amino-1,4(2H)-4-iminopyrimidine (ara-AlPy) and its 3'-phosphate (ara-AIPyP) have been synthesized and have been shown to be very effective in the treatment of leukemia L1210 in female C57BL/6 x DBA/2 (hereafter known as BDF1) mice (ara-AIPy increased life span 222% and cured 21 of 30 animals, ara-AIPyp increased life span 145% and cured 2 of 6 animals). The antileukemic activity of ara-AIPy is comparable to that of anhydro-ara-C. ara-AIPyP was also effective (i.p. treatments) against intracerebrally implanted leukemia L1210 in female BDF1 mice (increased life span 126%, cured 1 of 6 animals), ara-AIPyp was not active against a leukemia L1210 strain which was resistant to ara-C treatments. ara-AIPy and ara-AIPyP were not substrates for enzymic deamination by crude extracts of Escherichia coli. ara-AIPyP was a substrate for E. coli alkaline phosphatase. In a Tris-HCl buffer (pH 7.4, 37°) ara-AIPy hydrolyzed to provide 2,2'-anhydro-1-β-D-arabinofuranosylcytosine and 1-β-D-arabinofuranosylcytosine (ara-C). Most of the ara-C produced by hydrolysis of ara-AIPy over a 24-hr period was due to direct deamination of ara-AIPy. Some ara-C (<10%) was also produced due to the hydrolysis of 2,2'-anhydro-1-β-D-arabinofuranosylcytosine. Under identical conditions of hydrolysis, ara-AIPyP gave 2-2'-anhydro-β-D-arabinofuranosylcytosine 3'-phosphate and 1-β-D-arabinofuranosylcytosine 3'-phosphate. Studies illustrate that ara-AIPy and ara-AIPyP are new deaminase-resistant depot forms of ara-C.

UR - http://www.scopus.com/inward/record.url?scp=0018750224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018750224&partnerID=8YFLogxK

M3 - Article

C2 - 455296

AN - SCOPUS:0018750224

VL - 39

SP - 3129

EP - 3133

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 8

ER -